In this context, the combination of anti‐HER3 (patritumab) and anti‐MET (PHA665752) drugs was definitely effective against HER3/MET‐high SW1116 CRC cells, indicating the potential of the dual inhibition of HER3 and MET as targeting therapy in human CRC. This evidence concerns the gene ERBB3 and colorectal carcinoma.